SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MPLT

MapLight Therapeutics, Inc. (NASDAQ:MPLT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$5.94-$0.48 (-7.48%)
 
Market cap
$253M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 24, 2025
Market Cap$253.15M-57.5%
Revenue (ttm)$0
Net Income-$252.02M-145.1%
EPS-$5.44-119.4%
Shares Out42.62M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume357,935
Open$6.33
Previous Close$6.42
Day's Range$5.93 - $6.48
52-Week Range$5.92 - $40.43
Beta3.01
AnalystsBuy
Price Target$29.20(+391.58%)
Earnings Daten/a

About MPLT

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

Address
800 Chesapeake Drive, Redwood City, CA, 94063, US
Market Cap
253 million
Employees
133
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$2.99M
Bought
$65.54M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $32.71 (+450.7%)

1 firm rating MPLT in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From MPLT’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
1 Day
-7.48%
5 Days
-18.96%
1 Month
-27.21%
6 Months
-79.71%
1 Year
-57.54%

$MPLT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MPLT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MPLT's directors and management

Net Shares Purchased by Insiders−6M−3M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MPLT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MPLT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MPLT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MPLT

IWMiShares Russell 2000 ETF$2.08M
VXFVanguard Extended Market ETF$1.58M
VTIVanguard Morningstar Total Stock Market ETF$1.03M
IWOiShares Russell 2000 Growth ETF$684.15K
VTWOVanguard Russell 2000 ETF$580.81K
SCHASchwab U.S. Small-Cap ETF$572.54K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MPLT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
56.63
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
6
Sells
15
Buy Value
$65.54M
Distinct Buyers
2

Insider Score Trend Over Time

-6.5 since Aug 27
0255075100Aug 27 — Insider Score 58.0Aug 28 — Insider Score 58.0Aug 29 — Insider Score 58.0Aug 30 — Insider Score 58.0Aug 31 — Insider Score 58.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 54.0Sep 26 — Insider Score 53.6Sep 27 — Insider Score 53.9Sep 28 — Insider Score 53.9Sep 29 — Insider Score 53.5Sep 30 — Insider Score 53.1Oct 1 — Insider Score 52.4Oct 2 — Insider Score 47.0Oct 3 — Insider Score 52.0Oct 4 — Insider Score 52.3Oct 5 — Insider Score 52.4Oct 6 — Insider Score 51.9Oct 7 — Insider Score 51.7Oct 8 — Insider Score 51.5Oct 9 — Insider Score 51.3Oct 10 — Insider Score 50.9Oct 11 — Insider Score 52.3Oct 12 — Insider Score 52.3Oct 13 — Insider Score 52.3Oct 14 — Insider Score 52.1Oct 15 — Insider Score 52.0Oct 16 — Insider Score 51.9Oct 17 — Insider Score 51.7Oct 18 — Insider Score 52.3Oct 19 — Insider Score 52.0Oct 20 — Insider Score 52.0Oct 21 — Insider Score 52.0Oct 22 — Insider Score 51.9Oct 23 — Insider Score 51.8Oct 24 — Insider Score 51.7Oct 25 — Insider Score 51.5Aug 27Sep 25Oct 25

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ASDDefiance Autism Impact ETF1.36%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.25%
BBCVirtus Biotech Clinical Trials ETF0.20%
IBRNiShares Neuroscience and Healthcare ETF0.06%
FSEGFidelity Enhanced Small Cap Growth ETF0.05%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.